Skyrizi and Interstitial lung disease - a phase IV clinical study of FDA data

Summary:

Interstitial lung disease is reported as a side effect among people who take Skyrizi (risankizumab-rzaa), especially for people who are male, 60+ old, have been taking the drug for 6 - 12 months also take Entecavir, and have Psoriasis.

The phase IV clinical study analyzes which people have Interstitial lung disease when taking Skyrizi. It is created by eHealthMe based on reports of 45,344 people who have side effects when taking Skyrizi from the FDA, and is updated regularly.

What is Skyrizi?

Skyrizi has active ingredients of risankizumab-rzaa. eHealthMe is studying from 45,385 Skyrizi users. Check the latest studies of Skyrizi.

What is Interstitial lung disease?

Interstitial lung disease is found to be associated with 1,500 drugs and 1,839 conditions by eHealthMe. Check the latest studies of Interstitial lung disease.

On Jul, 06, 2026

45,344 people reported to have side effects when taking Skyrizi.
Among them, 41 people (0.09%) have Interstitial lung disease.

Could Skyrizi cause Interstitial lung disease?

Among these 41 people:

How long have people been on Skyrizi when they have Interstitial lung disease? *

What is the gender of people who have Interstitial lung disease when taking Skyrizi? *

female: 48.57 %
male: 51.43 %

What is the age of people who have Interstitial lung disease when taking Skyrizi? *

What are other drugs people take besides Skyrizi? *

What are other side effects people have besides Interstitial lung disease? *

Joint Pain: 4 people, 9.76%
Pneumonia: 4 people, 9.76%
Chest Pain: 4 people, 9.76%
Abdominal Distension: 3 people, 7.32%
Cell Marker Increased: 3 people, 7.32%
Pleural Effusion (water on the lungs): 3 people, 7.32%
Myocarditis (inflammation of heart muscle myocardium): 3 people, 7.32%
Scar Pain: 3 people, 7.32%
Acute Coronary Syndrome (acute chest pain and other symptoms that happen because the heart does not get blood): 3 people, 7.32%
Troponin Increased: 3 people, 7.32%

What are the existing conditions these people have? *

Psoriasis (immune-mediated disease that affects the skin): 27 people, 65.85%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 7 people, 17.07%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 6 people, 14.63%
High Blood Pressure: 4 people, 9.76%
Constipation: 3 people, 7.32%
Osteoporosis (bones weak and more likely to break): 3 people, 7.32%
Gastric Ulcer (stomach ulcer): 3 people, 7.32%
Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters): 2 people, 4.88%
Itching: 2 people, 4.88%
Type 2 Diabetes: 2 people, 4.88%

* Approximation only. Some reports may have incomplete information.

Do you take Skyrizi and have Interstitial lung disease?

- Check whether Interstitial lung disease is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Skyrizi:

Skyrizi (45,385 reports)

Browse all side effects of Skyrizi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Interstitial lung disease:

Interstitial lung disease (1,500 drugs)

Browse all the conditions that are associated with Interstitial lung disease:

Interstitial lung disease (1,839 conditions)

Related publications that referenced our studies

Thangakunam B, Christopher DJ, Mathews V, Srivastava A, "Mesenchymal stromal stem cell therapy in advanced interstitial lung disease-Anaphylaxis and short-term follow-up", Lung India: official organ of Indian Chest Society, 2015 Jan .
Kato, M., Oiso, N., Nozaki, Y., Inoue, A., Hosono, Y., Funauchi, M., ... & Kawada, A., "Antitumor necrosis factor alpha inhibitor‐induced dermatomyositis and interstitial lung disease with anti‐PL 12 autoantibody: Signs of antisynthetase syndrome", The Journal of dermatology, 2012 Jan .
Thangakunam B, Christopher DJ, Mathews V, Srivastava A, "Mesenchymal stromal stem cell therapy in advanced interstitial lung disease-Anaphylaxis and short-term follow-up", Lung India: official organ of Indian Chest Society, 2015 Jan .
Kato, M., Oiso, N., Nozaki, Y., Inoue, A., Hosono, Y., Funauchi, M., ... & Kawada, A., "Antitumor necrosis factor alpha inhibitor‐induced dermatomyositis and interstitial lung disease with anti‐PL 12 autoantibody: Signs of antisynthetase syndrome", The Journal of dermatology, 2012 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on risankizumab-rzaa (the active ingredients of Skyrizi) and Skyrizi (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.